Boris Pasche: Karmanos Cancer Institute Leads Innovation in Cancer and Hematologic Disease Treatment
Boris Pasche, President and CEO at Karmanos Cancer Institute, shared a post on LinkedIn:
“Karmanos Cancer Institute continues to lead in medical science by providing patients with exceptional treatment opportunities for cancer and hematologic diseases.
As a pioneer in Theranostics, phase I trials, medical devices, and now gene therapy for hemophilia, Karmanos exemplifies its mission to transform care, research, and education in these fields through courage, commitment, and compassion.
With 17 locations throughout Michigan, Karmanos also offers second opinions, often introducing patients to novel therapies they may not have previously considered.
For more information on their groundbreaking work, check out this article: Karmanos is first independent cancer center to treat hemophilia B with new gene therapy.”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers